Quite often we get bogged down with the share price and cul-de-sacs Cytori has entered. No doubt that the dilution that has taken place and the inability of the market to see the potential of this company is very frustrating.
We must not however forget that there is a group of scientists/researchers/doctors who are trying to succeed in bringing a novel cure/treatment to patients . They are trying for their own individual varied and multiple reasons ......... certainly it is not the desire to make us rich, per se.
The complexity of the whole exercise is immense. Looking at how one assesses wound healing and measuring it is no easy feat. It certainly was not easy in the past. The amount of data that is generated is also huge.
Its fascinating to see how Cytori is using technology like the Silhouette Camera system to help them realize their objectives in the BARDA contract. Lets hope that all this technology helps speed up the clinical trial process and provides patients to benefit from ADRC therapy quickly.